Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics

Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma (<i>R</i> > 0.99) and high quantitative precision, with a coefficient of variance (CV) below 10% for 80% of all peptides quantified in the group of healthy donors. All of the targets that perform well in the microsampling device also show good long-term stability when stored at room temperature for up to 232 days, further showcasing the potential benefits of collecting samples in a dry format.

Authors

Institutions

Publication Details

Journal
Analytical Chemistry
Published
2025-06-18
DOI
https://doi.org/10.1021/acs.analchem.4c05455
Citations
1
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics

Benjamin Challis, Marcus Henricsson, Pia Davidsson, Tasso Miliotis et al.
1 citations
Analytical Chemistry
Biosimilars and Bioanalytical Methods
0.80
article

Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics

Benjamin Challis, Marcus Henricsson, Pia Davidsson, Tasso Miliotis, Andreas Hober, Tim Ruckh
article en
1 citations

Abstract

Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma (<i>R</i> > 0.99) and high quantitative precision, with a coefficient of variance (CV) below 10% for 80% of all peptides quantified in the group of healthy donors. All of the targets that perform well in the microsampling device also show good long-term stability when stored at room temperature for up to 232 days, further showcasing the potential benefits of collecting samples in a dry format.

Analytical ChemistryVol. 97(25)
Digital China Health (China) (CN), AstraZeneca (Netherlands) (NL), AstraZeneca (Brazil) (BR), AstraZeneca (Finland) (FI), AstraZeneca (Sweden) (SE), Digital Health Cooperative Research Centre (AU)
Zero hunger
Openalex Percentile: Top 27%
Biosimilars and Bioanalytical Methods
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.